Deregulated signaling pathways in CTCL patients include the JAK-STAT pathway, MAP kinase signaling, p53 pathway, and NFkB signaling [1]. This evidence concerns the gene TP53 and primary cutaneous T-cell non-Hodgkin lymphoma.